A phase II open-label randomized clinical trial of preoperative durvalumab or durvalumab plus tremelimumab in resectable head and neck squamous cell carcinoma
Clin. Cancer Res., Mar 08 2024, | https://doi.org/10.1158/1078-0432.CCR-23-3249
Personalized Biomarker-Based Umbrella Trial for Patients With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: KCSG HN 15-16 TRIUMPH Trial.
J. Clin. Oncol., Sep 12 2023 | https://doi.org/10.1200/JCO.22.02786
Distinct exhaustion features of T lymphocytes shape the tumor-immune microenvironment with therapeutic implication in patients with non-small-cell lung cancer
J. Immunother. Cancer, Online issue publication December 14, 2021, 9:e002780 | doi: 10.1136/jitc-2021-002780
The Ratio of Peripheral Regulatory T Cells to Lox-1+ Polymorphonuclear Myeloid-derived Suppressor Cells Predicts the Early Response to Anti–PD-1 Therapy in Patients with Non–Small Cell Lung Cancer
Am. J. Respir. Crit. Care Med., Vol. 199, No. 2, Jan 15, 2019 | https://doi.org/10.1164/rccm.201808-1502LE